Biosurgery Market Analysis

The South America biosurgery market is driven by the region's large and growing surgical volumes, expanding healthcare infrastructure, and increasing adoption of advanced surgical technologies. Rising disease burden, alongside increasing prevalence of chronic conditions including cardiovascular disorders, cancer, and orthopedic conditions, continues to expand demand for biosurgical products such as hemostatic agents, surgical sealants, bone-graft substitutes, and adhesion barriers. Clinical adoption is supported by improving healthcare access, growing medical tourism, and the gradual adoption of minimally invasive surgical techniques, strengthening the region's position as an emerging market for surgical biomaterials. According to the research report, "South America Biosurgery Market Outlook, 2031," published by Actual Market Research, the South America Biosurgery Market is expected to reach a market size of more than 0.88 Billion by 2031.. Across South America, healthcare expenditure averages approximately 6.6% to 6.9% of GDP, well below the OECD average of 9.3%. Brazil leads with the largest population of 213.4 million people and 14.7 million elective surgeries performed through the Unified Health System (SUS) in 2025 a record high representing a 42% increase from 2022. Argentina's health spending stands at 10.36% of GDP (ranking 26th globally), having risen steadily from 8.22% of GDP in 2000. Colombia allocates 8.1% of GDP to healthcare, with household spending on health goods and services reaching 70.2 trillion pesos (6.9% of GDP) in 2025. These statistics highlight a diverse healthcare landscape across South America, supporting growing surgical volumes and driving demand for biosurgical products across all major surgical specialties. Brazil dominates the regional biosurgery market owing to its enormous population, massive surgical volumes through the SUS, and the presence of a robust medical device regulatory framework through ANVISA. Argentina supports steady demand through its high healthcare expenditure, with the public healthcare system serving a significant portion of the population.

Colombia represents the fastest-growing market in the region, driven by expanding healthcare access, universal health coverage (99% of the population), and increasing adoption of advanced surgical technologies. Across South America, the biosurgery market continues to benefit from technological innovation, including advanced hemostatic agents, synthetic sealants, and bioactive bone grafts. Regulatory modernization across the region, including ANVISA's updated medical device registration framework in Brazil and regulatory developments in Argentina and Colombia, is facilitating market access for innovative biosurgical products. Brazil is expected to retain market leadership, while Colombia and Argentina are projected to support future regional expansion through strengthening healthcare infrastructure, increasing awareness, and broader access to advanced biosurgical products. .

Market Dynamic

BiosurgerySegmentation

Surgical Sealants and Adhesives is the fastest-growing product segment because increasing adoption of minimally invasive surgical techniques across South American healthcare systems creates demand for advanced tissue-sealing solutions that can be delivered through small incisions.

Surgical Sealants and Adhesives represent the fastest-growing product category in the South America biosurgery market, driven by increasing adoption of minimally invasive surgical techniques. These products including fibrin sealants, synthetic polymer-based sealants, and protein-based adhesives are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses. South America is witnessing a gradual shift toward laparoscopic and endoscopic surgeries in major metropolitan areas, creating new opportunities for surgical sealants and adhesives that can be delivered through small incisions. The growing demand for advanced surgical technologies supports the expansion of this segment. Continuous product innovation, including synthetic sealants with enhanced wet-tissue adhesion, is expanding the addressable market and creating new clinical applications across cardiovascular, general, and thoracic surgeries. Brazil leads in the adoption of these advanced sealant technologies in the region, supported by large surgical volumes and the presence of private healthcare networks that invest in advanced surgical technologies.

Cardiovascular Surgery is the fastest-growing application segment because rising cardiovascular disease prevalence, aging populations, and technological advancements in cardiac procedures are increasing demand for vascular sealants, hemostatic agents, and soft-tissue attachments.

Cardiovascular Surgery represents the fastest-growing application area in the South America biosurgery market, driven by the high prevalence of cardiovascular disease and the aging population. Cardiovascular diseases are among the leading causes of death and household health spending in South American countries. In Brazil, the SUS performed 367,100 oncological surgeries in 2025, reflecting the growing burden of non-communicable diseases. Vascular sealants, hemostatic agents, and soft-tissue attachments are increasingly utilized in cardiac and vascular procedures, including coronary artery bypass grafting, valve replacements, and vascular reconstructions. The growing adoption of minimally invasive cardiac surgery techniques is creating new opportunities for advanced biosurgical products designed for smaller incisions and precision delivery. Technological innovations, including synthetic sealants with enhanced adhesion and hemostatic agents with faster action times, are expanding the addressable market and driving adoption across cardiac surgery centers. Brazil, with its large population and expanding cardiac surgical infrastructure, leads the adoption of biosurgical products in cardiovascular applications in the region.

Synthetic and Semi-Synthetic products are the fastest-growing source category because cost-effectiveness, consistent quality, and lower immunogenicity risks support adoption across price-sensitive healthcare markets in South America.

Synthetic and Semi-Synthetic products represent the fastest-growing source category in the South America biosurgery market, driven by cost-effectiveness, consistent quality, and lower immunogenicity risks. These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats. The growing emphasis on cost-containment in South American healthcare systems favors synthetic alternatives for certain applications. With healthcare expenditure well below OECD averages across the region, price sensitivity drives demand for cost-effective synthetic products. Technological innovations, including advanced synthetic polymers and bio-inspired materials, are improving clinical outcomes and expanding the addressable market. The emphasis on cost-effectiveness in healthcare systems, combined with consistent quality and reduced immunogenicity risks, supports the growing adoption of synthetic alternatives across South American healthcare facilities.

Ambulatory Surgical Centers are the fastest-growing end-user segment because the shift toward outpatient and same-day discharge models, cost-efficiency, and technological advancements are increasing procedure volumes in ASC settings across South America.

Ambulatory Surgical Centers (ASCs) represent the fastest-growing end-user segment in the South America biosurgery market, driven by the broader healthcare industry shift toward outpatient and same-day discharge models. The expansion of outpatient surgical capacity, supported by both public and private healthcare sectors across the region, supports the adoption of biosurgical products in these settings. Technological advances enabling more complex procedures to be performed safely in outpatient settings, patient preference for convenience, and payer initiatives to reduce healthcare expenditure are driving ASC growth. For biosurgery manufacturers, this trend requires adaptation of product portfolios developing formulations and delivery systems optimized for the fast-paced, high-throughput ASC environment and adjustment of commercial strategies to target the growing ASC customer base. Brazil leads in ASC-based biosurgical product adoption in the region, supported by the presence of private healthcare networks and growing outpatient surgical capacity.

Biosurgery Market Regional Insights

Brazil dominates the South America biosurgery market because vast healthcare infrastructure, massive surgical volumes through SUS, and regulatory modernization through ANVISA support widespread biosurgical product utilization.

Brazil represents the largest contributor to the South America biosurgery market due to its vast healthcare ecosystem, immense surgical volumes, and strong regulatory framework through ANVISA. Brazil's population reached 213.4 million in 2025. The Unified Health System (SUS) performed 14.7 million elective surgeries in 2025 a record high. Brazil's elderly population (60 years and older) reached 16.6% of the total population in 2025, up from 11.3% in 2012. ANVISA processed 10,639 new medical device registration records in 2025 the highest annual total in the agency's history. Brazil's medical device market is among the top 15 globally, with the medical technology market generating approximately R$ 80 billion (USD 15.5 billion) in apparent consumption in 2025. Brazil is expected to retain its dominant position in the South America biosurgery market during the forecast period.
Argentina and Colombia provide significant growth opportunities because rising surgical procedure volumes, healthcare infrastructure expansion, and improving access to specialized surgical services are supporting biosurgery market development.

Argentina represents a significant biosurgery market with high healthcare expenditure of 10.36% of GDP in 2025, ranking 26th globally. Argentina's health spending has risen steadily from 8.22% of GDP in 2000. The country has 3,951 health establishments with hospitalization and 25,808 without hospitalization. Argentina's population is estimated at 45.9 million in 2025. The country has established itself as a destination for medical tourism, with more than 28,000 annual aesthetic interventions. Argentina's biosurgery market witnessed a steady increase in imports from 2020 to 2024, with a CAGR of 3.65%. ANMAT regulatory modernization continues to facilitate market access. Colombia represents the fastest-growing biosurgery market in South America. Colombia has achieved 99% healthcare coverage of its population. Healthcare expenditure reached 8.1% of GDP in 2025. Household spending on health goods and services reached 70.2 trillion pesos (6.9% of GDP) in 2025. Colombia's population reached 53.3 million in 2025. The country performed 490,944 aesthetic procedures in 2024, including 321,408 surgical procedures, representing a 10% increase. Colombia recorded 148 companies engaged in hospital equipment exports, with external sales of USD 81 million in 2025. INVIMA regulates medical devices under Decree 4725 of 2005. Colombia's healthcare budget has grown at an average annual real rate of 6.5% between 2000 and 2025.